Outdated System Preventing Breast Cancer Patients Getting Access To Early Treatment In England, Says Roche
Executive Summary
Roche Pharma AG has been scorned once again by the England's health technology appraisal body NICE – with the pricing group this time rejecting the big pharma's breast cancer treatment Perjeta (pertuzumab) for regular use on the NHS as a neoadjuvant therapy.
You may also be interested in...
NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut
The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.
EU gives go-ahead for Roche's Perjeta with further 2013 approvals to follow
Roche said it anticipates further approvals this year for its targeted breast cancer drug Perjeta (pertuzumab), having secured EU approval for the product to be used in patients with previously untreated HER2-positive metastatic breast cancer (mBC).
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.